John W. Rollins - 19 Feb 2026 Form 4 Insider Report for 20/20 Biolabs, Inc.

Role: Director
Signature: /s/ John W. Rollins
Issuer symbol: N/A
Transactions as of: 19 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 23 Feb 2026, 19:09:32 UTC
Previous filing: 23 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rollins John Woodson	Director	C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG	/s/ John W. Rollins	23 Feb 2026	0002112941

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction		Common Stock	Conversion of derivative security	$0	+13,029	+117%	$0.000000	24,140	19 Feb 2026	Direct	F1
transaction		Common Stock	Conversion of derivative security	$0	+6,135	+25%	$0.000000	30,275	19 Feb 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction		Series A Preferred Stock	Conversion of derivative security		-13,029	-100%		0	19 Feb 2026	Common Stock	13,029		Direct	F1
transaction		Series A-2 Preferred Stock	Conversion of derivative security		-6,135	-100%		0	19 Feb 2026	Common Stock	6,135		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date.
F2	On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.